FDA approves Watson's generic BONIVA ANDA to treat osteoporosis in women

Download PDF Copy

Mar 21 2012

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Ibandronate 150mg tablets, the generic equivalent to Roche's BONIVA® tablets.

Watson intends to begin shipping the product in the second quarter. BONIVA® 150mg tablets had total U.S. sales of approximately $510 million for the twelve months ending January 31, 2012, according to IMS Health. Ibandronate tablets are indicated to prevent and treat osteoporosis in women who have undergone menopause. Roche has sued Watson for patent infringement in connection with Watson's ANDA for Ibandronate 150mg tablets. That lawsuit remains pending.

SOURCE Watson Pharmaceuticals, Inc.

Posted in: Women's Health News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Gut microbiota and short chain fatty acids influence bone health in postmenopausal osteoporosis

Researchers discover amyloid protein buildup in bone marrow of aging mice

$Walking faster may protect your bones and prevent fractures$

Walking faster may protect your bones and prevent fractures

Curcumin activates SIRT3 to protect bone structure in diabetic mice

Exploring testosterone's influence on cardiovascular, metabolic, reproductive, and mental health

PEPITEM shows promise in treating osteoporosis by enhancing bone health

Egg yolk compound shows promise in osteoporosis management

Adults over 80 benefit from osteoporosis medications

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.